American Diabetes Association Scientific Sessions

American Diabetes Association Scientific Sessions

Issue: August 2021
Source: Healio interview
Disclosures: Kosiborod reports he has financial ties with numerous drug and device companies. Pratley reports no relevant financial disclosures.
June 27, 2021
1 min watch
Save

VIDEO: SGLT2 inhibitors may protect organs in acute illness

Issue: August 2021
Source: Healio interview
Disclosures: Kosiborod reports he has financial ties with numerous drug and device companies. Pratley reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video exclusive, Richard E. Pratley, MD, talks with Mikhail Kosiborod, MD, FACC, FAHA, about the DARE-19 trial, which explored repurposing existing medications to treat COVID-19.

Pratley is the Samuel E. Crockett Chair in Diabetes Research and medical director of AdventHealth Diabetes Institute, and Kosiborod is vice president for research and the Ben McCallister, MD, Endowed Chair in Cardiovascular Research at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine.

The rationale behind studying SGLT2 inhibitors for COVID-19 treatment lay in their mechanism of action and data from clinical trials that this drug class can provide organ protection in patients under stable conditions. DARE-19 extended the investigation to similar patients under more acute circumstances, such as COVID-19, Kosiborod said.

Pratley and Kosiborod discuss the quickly changing event rate during the COVID-19 pandemic, the hypothesis that SGLT2 can provide organ protection in acute illness beyond COVID-19, and the current practice of discontinuing SGLT2 inhibitors in the hospital.